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Abstract
Objectives To examine whether rate of reoperation after breast
conserving surgery is associated with patients’ characteristics and
investigate whether reoperation rates vary among English NHS trusts.
Design Cohort study using patient level data from hospital episode
statistics.
Setting English NHS trusts.
Participants Adult women who had breast conserving surgery between
1 April 2005 and 31 March 2008.
Main outcome measure Reoperation rates after primary breast
conserving surgery within 3 months, adjusted using logistic regression
for tumour type, age, comorbidity, and socioeconomic deprivation.
Tumours were grouped by whether a carcinoma in situ component was
coded at the time of the primary breast conserving surgery.
Results 55 297 women had primary breast conserving surgery in 156
NHS trusts during the three year period. 11 032 (20.0%, 95% confidence
interval 19.6% to 20.3%) women had at least one reoperation. 10 212
(18.5%, 18.2% to 18.8%) had one reoperation only; of these, 5943
(10.7%, 10.5% to 11.0%) had another breast conserving procedure and
4269 (7.7%, 7.5% to 7.9%) had a mastectomy. Of the 45 793 women
with isolated invasive disease, 8229 (18.0%) had at least one reoperation.
In comparison, 2803 (29.5%) of the 9504 women with carcinoma in situ
had at least one reoperation (adjusted odds ratio 1.9, 95% confidence
interval 1.8 to 2.0). Substantial differences were found in the adjusted
reoperation rates among the NHS trusts (10th and 90th centiles 12.2%
and 30.2%).
Conclusion: One in five women who had breast conserving surgery in
England had a reoperation. Reoperation was nearly twice as likely when
the tumour had a carcinoma in situ component coded. Women should
be informed of this reoperation risk when deciding on the type of surgical
treatment of their breast cancer.
Introduction
Each year, 430 000 new cases of breast cancer are diagnosed
in Europe and 250 000 in the United States.1 2 In England,
around 45 000 women are diagnosed as having breast cancer
annually,3 and in 2008 58% had breast conserving surgery.4
Breast conserving surgery involves removing only part of the
affected breast and, when combined with postoperative
radiotherapy, produces survival rates similar to those achieved
with mastectomy alone for women with invasive disease.5 The
choice of breast conserving surgery or mastectomy depends on
the extent of the cancer, the size of the tumour relative to the
size of the breast, its location, and the patient’s preference.
Preoperative chemotherapy may reduce the size of a tumour to
allow breast conserving surgery, but a slightly higher risk of
local recurrence exists compared with mastectomy.6
The adoption of breast conserving surgery has been aided by
advances in imaging techniques and the use of radiologically
placed guide wires.7 8 Both have improved surgeons’ ability to
localise tumours. However, certain circumstances can complicate
breast conserving surgery. Firstly, surgery becomes more
complex for multifocal disease, which is found in up to 35% of
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womenwith breast cancer.9 Secondly, womenmay have invasive
disease, carcinoma in situ (non-invasive disease) only, or a
combination of both. Identifying the presence and extent of a
carcinoma in situ component is more difficult using standard
clinical or radiological techniques than is isolated invasive
disease.10 Primary breast conserving surgerymay therefore result
in incomplete excision of cancer or inadequate clearance
margins, which both typically require women to have
reoperation to the breast.11 This is usually done as soon as
possible to minimise the delay to adjuvant treatments, which
could increase the risk of recurrence. A breast reoperation may
involve a further breast conserving procedure or mastectomy.
Reoperation after breast conserving surgery has various
undesirable consequences. It may delay adjuvant treatments,
and some evidence suggests that it is associated with increased
rates of local and distant recurrence.7 12 13 It is likely to cause a
significantly poorer cosmetic outcome, regardless of whether
the reoperation is a second breast conserving procedure or a
mastectomy.14 Reoperation also puts women through the
emotional distress of being told that their cancer has not been
completely excised and leads to delays in their recovery. This
extended recovery period can hinder the ability of women to
resume work and other activities, so it has an adverse
socioeconomic effect. The additional procedures also represent
a burden to the healthcare system in terms of potentially
avoidable financial costs and lower levels of productivity.
Few studies have examined reoperation rates after breast
conserving surgery, and uncertainty exists about how likely
women are to need reoperation. Estimated rates from
international hospital based studies have ranged from 17% to
68%.10 11 15-18 In this study, we estimated rates of breast
reoperation after primary breast conserving surgery among
women treated in English NHS trusts. We examined whether
rate of reoperation after breast conserving surgery was associated
with patients’ characteristics and whether reoperation rates
varied among English NHS trusts. The NHS does close to 90%
of breast cancer surgery in England.19
Methods
Patient selection and definitions
The study used data extracted from the hospital episode
statistics. This database contains records describing the type,
timing, and location of all surgery for breast cancer among
patients admitted to NHS acute trusts in England.20 Patients’
diagnoses, comorbidities, and complications are coded using
ICD-10 (international classification of diseases, 10th revision),21
and procedures are coded using the classification of surgical
operations from the UK Office of Population Censuses and
Surveys (OPCS), version 4.22
This study included all women aged over 16 years with a
diagnosis of invasive carcinoma (ICD-10 code: C50) or
carcinoma in situ (D05) of the breast who had unilateral breast
conserving surgery between 1 April 2005 and 31 March 2008.
The three digit code for carcinoma in situ covers both ductal
(D05.1) and lobular (D05.0) carcinoma in situ, but the subtype
may be left unspecified (D05.9). Although most women with a
D05 code had ductal carcinoma in situ, the proportion of women
with an unspecified subtype varied between NHS trusts. We
therefore used the three digit ICD-10 code to avoid artificially
introducing variation.
We used diagnostic information in the record of the primary
surgery to identify tumour type. We grouped women according
to whether or not a carcinoma in situ component was recorded
instead of the presence or absence of invasive disease, the more
common approach. This was because tumours with a carcinoma
in situ component are considered to be more difficult to localise
preoperatively, making them harder to excise completely.10 23
In English NHS trusts, coders first record information on
diagnosis (C50, D05, or both) based on preoperative biopsy
findings. They then amend these diagnoses, if required, after
receipt of the definitive postoperative histology results.
We identified primary breast conserving surgery (OPCS codes
B28.1, B28.2, B28.3, B28.5, B28.8, and B28.9) andmastectomy
(B27) procedures. As hospital episode statistics do not contain
the date of diagnosis of cancer, we reviewed each woman’s
hospital admissions in the preceding year to ensure that the
breast conserving surgery operation identified between April
2005 andMarch 2008 was their first procedure for breast cancer.
We identified subsequent breast conserving procedures done
on the same breast (that is, coded with the same laterality) by
using a range of breast operation codes (B28.1, B28.2, B28.3,
B28.4, B28.5, B28.8, and B28.9) (see appendix for description
of codes). This was because the specific code for re-excision of
breast margins (B28.4) was not used consistently across NHS
trusts. We also identified subsequent mastectomies (B27) done
on the same breast after the initial primary breast conserving
surgery. We excluded 27 subsequent operations done within
one week of the primary breast conserving surgery, assuming
that they were for postoperative complications. We limited the
definition of reoperation to procedures done within three months
to avoid including operations to treat early local recurrence.
We recorded age at admission, comorbidity, and socioeconomic
deprivation. We used the Royal College of Surgeons of
England’s modified Charlson score to calculate comorbidity.24
This sums the number of chronic comorbid conditions
(excluding cancer) recorded in the index admission and the
number of acute or chronic comorbid conditions recorded in
any hospital admissions over the previous year. We used the
area based index of multiple deprivation for 2007 to measure
socioeconomic deprivation.25 The index combines indicators of
income, employment, education, and health deprivation for
small geographical areas of about 1500 people. We assigned
the deprivation score by using the patient’s area of residence
and then grouped patients into five categories ranging from 1
(least deprived) to 5 (most deprived) divided by the quintiles
of the scores.
Statistical analysis
We calculated reoperation rates for England overall, for various
groups of patients, and for each NHS trust. We used the χ2 test
to assess differences between unadjusted rates. All P values
were two sided, and we considered those lower than 0.05 to be
statistically significant.
We usedmultivariable logistic regression to examine the relation
between the risk of reoperation and patients’ characteristics (age
at admission, tumour group, comorbidity, and socioeconomic
deprivation). We then used this model to derive risk adjusted
reoperation rates for each NHS trust. We summed the
probabilities of reoperation for women treated at the same NHS
trust to give its predicted rate of reoperation. We produced risk
adjusted reoperation rates for each NHS trust by dividing its
unadjusted reoperation rate by its predicted rate and multiplying
this ratio by the national reoperation rate.
We used a funnel plot to examine the variation in adjusted
reoperation rates among the NHS trusts that did more than 30
primary breast conserving surgery procedures over the three
year period.26 This plot tests whether the reoperation rate of a
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trust differs significantly from the national rate for England.
Two funnel limits indicate the ranges within which 95% or
99.8% of NHS trusts would be expected to fall if variation from
the national rate was due only to random fluctuations. We used
Stata version 10 for all calculations.
Results
Between 1 April 2005 and 31 March 2008, we identified 104
917 women with breast cancer who had primary breast cancer
surgery at 163 English NHS trusts. We excluded 4293 (4.1%)
women who had simultaneous operations on both breasts and
4742 (4.5%) with primary procedures that did not have the
laterality coded. This left 95 882 women in the analysis cohort.
Of these women, 55 297 (57.7%) had breast conserving surgery
and 40 585 (42.3%) hadmastectomy as their primary therapeutic
procedure (fig 1⇓).
Among the 55 297 women who had primary breast conserving
surgery, 45 793 (82.8%) had isolated invasive disease, 6622
(12.0%) had isolated in situ disease, and 2882 (5.2%) had both
invasive and in situ disease coded in their primary breast
conserving surgery record. Thus, a total of 9504 (17.2%) women
had a carcinoma in situ component recorded at the time of the
primary breast conserving surgery.
Reoperation rates after primary breast
conserving surgery
In the three months after primary breast conserving surgery, 11
032 (20.0%, 95% confidence interval 29.6% to 20.3%) of the
55 297 women had at least one breast reoperation. Of these, 10
212 women had one reoperation—5943 had further breast
conserving surgery, and 4269 had a mastectomy, corresponding
to rates of 10.7% (10.5% to 11.0%) and 7.7% (7.5% to 7.9%).
The remaining 820 (1.5%, 1.4% to 1.6%) women had two or
more reoperations. This means that, of the 5943 women who
had a second breast conserving procedure, 13.8% (12.9% to
14.7%)were again found to have inadequatemargins and needed
at least one more reoperation.
Reoperation rates differed between women with and without
carcinoma in situ coded (table 1⇓). Women with a carcinoma
in situ component coded were more likely to have at least one
reoperation (29.5% v 18.0%, P<0.001). Among women who
had just one reoperation, the proportion that had mastectomy
rather than a second breast conserving procedure was not
associated with whether or not their tumours had a carcinoma
in situ component coded (41.6% v 41.9%, P=0.77).
Reoperation was less likely in older women and in those with
more comorbid conditions (table 2⇓). Reoperation rates were
marginally lower among women frommore deprived areas. The
increased risk of reoperation among women with a carcinoma
in situ component coded persisted after adjustment for these
factors (adjusted odds ratio 1.9, 95% confidence interval 1.8 to
2.0).
Reoperation rates at individual NHS trusts
One hundred and forty-eight English NHS trusts did more than
30 primary breast conserving surgery procedures over the three
year period (the “minimum volume” criterion excluded 58
women). We excluded a further 306 women for whom
information about their age and deprivation category was
missing (table 2⇓).
The reoperation rate among women who had breast conserving
surgery varied significantly across the 148 trusts (fig 2⇓); the
10th and 90th centiles of the rates were 12.4% and 29.5%. The
effect of adjusting the reoperation rates for patients’
characteristics (age at admission, tumour group, comorbidity,
and socioeconomic deprivation) differed across the trusts; 11
values changed by an absolute value of at least 2%. However,
this did not reduce the between trust variation overall (fig 3⇓).
The 10th and 90th centiles of the adjusted reoperation rates were
12.2% and 30.2%.We found no evidence that reoperation rates
were related to the level of activity at an NHS trust.
Discussion
Reoperation after breast conserving surgery for breast cancer
can result in a poorer cosmetic outcome compared with
mastectomy, and evidence shows that reoperation is associated
with increased rates of local and distant recurrence.7 27 28. One
in five women who had primary breast conserving surgery in
the English NHS between April 2005 and March 2008 needed
a breast reoperation within three months. Moreover, among
women who had breast conserving surgery as a reoperation, one
in seven needed further surgery. Reoperation wasmore common
among women with a carcinoma in situ component recorded at
the time of the primary breast conserving surgery than in those
without (29.5% v 18.0%). It was also more common among
younger women.
A fourfold variation existed in the reoperation rate between the
English NHS trusts. This raises questions about the uniformity
of the selection criteria for both primary breast conserving
surgery and reoperation, and it highlights the need for cancer
networks and professional organisations to develop initiatives
aimed at reducing the risk of reoperation. The current situation
is unsatisfactory as it results in women having experiences of
care that depend on where they are treated. This is of concern
because around 40% of women who had a reoperation after
breast conserving surgery ended up having a mastectomy. The
reasons for the lower rates of reoperation at particular NHS
trusts should be explored so that lessons can be learnt and
disseminated.
Strengths and limitations of study
Our study has several strengths. It used a comprehensive national
database, which reduces the risk of selection bias. We focused
on breast reoperation rates and did not include subsequent
operations to the axilla, and we required primary and subsequent
procedures to have the same laterality to avoid including
contralateral procedures as reoperations. We chose to estimate
reoperation rates by provider and not by surgical team, because
NHS trust is reliably coded in hospital episode statistics, whereas
the coding of surgical team has not been validated, and because
the volume of activity at the level of the surgeon would give
limited statistical precision. Finally, the timeframe for
classifying subsequent procedures as reoperation avoided
inclusion of operations for complications or for early local
recurrence. As a sensitivity analysis, follow-up was extended
to six months (used by some studies), and we found that this
had little effect: the overall reoperation rate increased from
20.0% to 20.6%.
The hospital episode statistics database does not include records
of treatment in private hospitals, and a small number of women
who have their primary breast conserving surgery in an NHS
hospital would have had a therapeutic reoperation in a private
hospital. This migration will have lowered our estimates of
overall reoperation rates, although the degree of underestimation
is likely to be minimal. The effect on the rates of NHS trusts is
also likely to be small compared with the variation observed.
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Another limitation is the potential for inaccuracies in the coding
of diagnoses and procedures within hospital episode statistics.29
Reoperation rates would be affected by the omission or
miscoding of the procedure and laterality of the operation.
However, validation work done for breast cancer surgery
suggests that procedure codes in hospital episode statistics are
accurate, with 90-93% agreement with data provided by
surgeons across English regions.30 We used a wide range of
codes to identify reoperations to minimise the effect of coding
errors on the observed reoperation rate. As a result, we expect
the overall effect of coding errors to be small.
Our results would be influenced by the accuracy of the coding
of a carcinoma in situ component. Clinical coding teams record
information on diagnosis (C50, D05, or both) based on
preoperative biopsy findings initially and then amend these
diagnoses, if necessary, after receipt of the definitive
postoperative histology results. In other words, we categorised
women on the basis of their postoperative diagnosis, whereas
decisions about whether to do breast conserving surgery were
based on the histological diagnosis available before surgery.
Overall, 17% of women in the hospital episode statistics were
coded as having carcinoma in situ. This is similar to another
large retrospective study,31 although other studies have reported
higher prevalence rates.32 Such misclassification would result
in an overestimate of the reoperation rate among women with
only invasive disease, and the relative risk between the risk of
reoperation and the presence of carcinoma in situ would be
underestimated owing to “regression dilution.”33
Finally, the hospital episode statistics database does not contain
information on some potential confounders such as lobular
histology, location and size of tumour, mammographic density,
and lymphovascular invasion.7 27 34 Omission of these factors
from the risk adjustment model could reduce its discriminatory
performance. However, differences in the prevalence of these
characteristics among NHS trusts are unlikely to account for
the large variation observed between organisations.
Comparison with other studies
Reported reoperation rates after primary breast conserving
surgery vary considerably. Some single centre series found rates
varying from 17% to 68%.15-18 31 34 The UK NHS Breast
Screening Programme reported a 22% therapeutic reoperation
rate for invasive disease and a 26% rate for isolated non-invasive
disease among a sample of UK surgeons in 2007-08.10 The UK
All Breast Cancer report reported that 20% of patients with
invasive disease and 29% of women with non-invasive disease
had repeat operations.28Overseas, a study from the Netherlands
which combined data from 16 hospitals on 961 patients reported
a reoperation rate of 28.9%; around 50% of these reoperations
were mastectomies.18 Using data on 2206 women who had
invasive disease from four specialist centres in the United States,
another study reported that 23% of women had one reoperation,
9% had two reoperations, and 1% had three reoperations.31 A
study from Germany of 565 women reported an overall
reoperation rate of 21.4% and rates of 10% and 29% for women
with and without an in situ component.34
Comparing the results of studies on reoperation rates after breast
conserving surgery is hampered by differences in the enrolled
populations and variable definitions, particularly across studies
from different countries.18 Our results are broadly similar to
those of other UK and international studies, but caution is
needed owing to methodological differences. The NHS Breast
Screening Programme was based on women with cancers
detected by screening, who are likely to have relatively small
tumours with a lower grade and stage. The All Breast Cancer
report (which combined cancer registry and hospital episode
statistics data) included all primary operations (breast conserving
surgery and mastectomy) for men and women diagnosed as
having breast cancer, and the derivation of repeat operation
included axillary surgery as well as re-excision of breast tissue.
Implications of our findings for clinical
practice
Breast conserving surgery followed by radiotherapy has been
shown to give the same survival benefit as mastectomy for
women with localised tumours.6 The choice between breast
conserving surgery and mastectomy therefore depends on
balancing the need to achieve complete excision of the tumour
with patients’ preferences about cosmetic appearance. Clinical
factors that influence this choice include the type, location, and
spread of the tumour, multifocal disease, the ratio of tumour
size to breast size, and the use of neoadjuvant systemic
treatment.18Our results highlight the importance of women also
being made aware of the local rates of reoperation after primary
breast conserving surgery when choosing their primary
treatment, along with the likelihood of proceeding to
mastectomy. In addition, our results emphasise the importance
of offering mastectomy with immediate breast reconstruction
as an alternative primary treatment option to women unless
significant comorbidity or planned adjuvant treatment precludes
this option.6 This option preserves the breast mound while
making further therapeutic reoperation extremely unlikely.
An important finding of our study is that reoperation rates after
breast conserving surgery were higher in women with a
carcinoma in situ component recorded at the time of their
primary surgery. Although postoperatively identified carcinoma
in situ at the invasive tumour margin is generally accepted to
be a cause of inadequate surgical margins,6women in this study
without an invasive component must have had their in situ
disease identified preoperatively. This suggests that the problem
partly relates to difficulties in identifying the extent rather than
just the presence of carcinoma in situ, because many such
tumours are multifocal.7 35 Greater use of imaging techniques,
such as whole breast ultrasonography,9 may help to reduce this
problem.
Interpreting variation in reoperation rates
between English NHS trusts
Our study showed that some English NHS trusts had adjusted
reoperation rates below 10%, whereas for others it was above
30%. The variation was evident across NHS trusts that had low,
medium, and high levels of activity, and we found no evidence
of a volume-outcome relation. Surgery for early breast cancer
is regarded as “preference sensitive” care, in which between
provider variation may be legitimate because it reflects patients’
preferences for alternative treatment options.36 For this reason,
expecting all NHS trusts to have the same underlying reoperation
rate would be unreasonable. However, the variation is
sufficiently large to suggest that it reflects differences in clinical
practice at various points during the therapeutic pathway, as
well as patients’ preferences. Practice related causes of variation
could include differences in selection protocols for breast
conserving surgery, poor surgical technique, and differences in
how resection margins are assessed (although the effect of this
last could be small given the national pathology reporting
guidelines6). Nonetheless, the worse outcomes associated with
reoperation mean that efforts are needed to reduce the risk of it
occurring. As discussed above, this may come from improved
imaging. The systematic practice of cavity margin resection has
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also been advocated as a means to reduce the likelihood of
surgical re-excision.37
An important cause of variation among these clinical factors is
probably the lack of consensus on what constitutes an adequate
excision margin, particularly when adjuvant radiotherapy is
planned. The US National Cancer Institute has questioned the
need for completely clear microscopic margins in breast
conserving surgery,38 whereas the National Institute for Health
and Clinical Excellence in England has recommended a
minimum 2 mm radial excision margin for ductal carcinoma in
situ but has not recommended margins for invasive disease.6 In
Canada, national guidelines apply only to invasive disease and
recommend that margins are microscopically clear and that any
involved margins should be re-excised.39 This lack of consensus
also affects research in this area, as studies adopt varying
definitions of positive margin status.40 The uncertainty about
adequate excision margins has led the Association of Breast
Surgery to recommend that UK hospitals should develop their
own local protocols for reoperation.41 Research is urgently
needed on how different approaches of dealing with incomplete
margins influence the likelihood of local recurrence.
For these reasons, interpreting these reoperation rates derived
from hospital episode statistics as indicators of the quality of
care at individual trusts cannot be justified. Information on local
protocols is lacking, and data on potential confounders is too
limited in hospital episode statistics.26 In addition, data on rates
of local recurrence are unavailable, and NHS trusts with low
reoperation rates as well as those with high rates could have
higher rates of recurrence. We suggest that the rate of
reoperation would be a reliable measure of hospital performance
only if it is derived in the context of a national clinical audit
that has the requisite data items.
Conclusion
Just over half of women diagnosed as having breast cancer in
England now select breast conserving surgery as their primary
treatment. Cosmetic outcomes after surgery for breast cancer
are an important consideration, and women should be made
aware of the local rates of reoperation after primary breast
conserving surgery, along with the likelihood of proceeding to
mastectomy. In addition, breast cancer teams should do a local
review of surgical technique, the definition of an adequate
excision margin, imaging methods, and criteria for selecting
patients. This may lead to an overall reduction in the reoperation
rate after breast conserving surgery.
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What this study adds
One in five women who had primary BCS in the English NHS between April 2005 andMarch 2008 needed at least one breast reoperation
within three months; about 40% of these had a mastectomy
Reoperation was more common among women with a carcinoma in situ component recorded at the time of the primary BCS than in
those with isolated invasive carcinoma (29.5% v 18.0%)
Reoperation rates varied substantially between NHS trusts, raising questions about the uniformity of the selection criteria for both primary
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Tables
Table 1| Patterns of breast reoperation within three months of primary breast conserving surgery, categorised by type of tumour
Women with carcinoma in situ diseaseWomen without carcinoma in situ disease
Patient group % (95% CI)No% (95% CI)No
950445 793Women who had breast conserving surgery
70.5 (69.6 to 71.4)670182.0 (81.7 to 82.4)37 564Women who had no reoperation
Women who had one reoperation:
15.8 (15.1 to 16.6)15029.7 (9.4 to 10.0)4441Additional breast conserving operation
11.2 (10.6 to 11.9)10687.0 (6.8 to 7.2)3201Mastectomy
2.5 (2.2 to 2.8)2331.3 (1.2 to 1.4)587Women who had two or more reoperations
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4505 doi: 10.1136/bmj.e4505 (Published 12 July 2012) Page 7 of 9
RESEARCH
Table 2| Proportions of women having breast reoperation after primary breast conserving surgery in English NHS hospital organisations
between 2005 and 2008
P valueAdjusted odds ratio* (95% CI)
Unadjusted odds
ratio
No (%) women with breast
reoperationAll womenCharacteristic
Type of tumour:
<0.001118229 (18.0)45 793Without in situ disease coded
1.91 (1.81 to 2.01)1.912803 (29.5)9504With in situ disease component
coded
Age (years):
<0.0011.15 (1.04 to 1.28)1.07530 (22.6)2348<40
1.30 (1.22 to 1.38)1.242056 (25.2)816540-49
113446 (21.4)16 12950-59
0.88 (0.84 to 0.93)0.873450 (19.1)18 04760-69
0.67 (0.63 to 0.72)0.631550 (14.6)10 599≥70
Index of multiple deprivation:
0.08112661 (20.7)12 8621 (least deprived)
0.96 (0.90 to 1.02)0.972547 (20.1)12 6452
0.93 (0.88 to 0.99)0.932283 (19.6)11 6733
0.93 (0.87 to 0.99)0.931952 (19.6)99684
0.94 (0.87 to 1.00)0.931527 (19.5)78435 (most deprived)
No of comorbidities:
0.04119855 (20.2)48 6970
0.96 (0.89 to 1.03)0.881095 (18.3)59911
0.73 (0.57 to 0.92)0.6182 (13.5)609≥2
*Based on complete case analysis, which excluded 306 (0.6%) women without index of multiple deprivation score; age was also unknown for six of these women.
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Figures
Fig 1 Inclusion of patients in study
Fig 2Unadjusted breast reoperation rates in English NHS acute hospital organisations for women who had breast conserving
surgery for breast cancer between 2005 and 2008. BCS=breast conserving surgery
Fig 3 Risk adjusted breast reoperation rates in English NHS acute hospital organisations for women who had breast
conserving surgery for breast cancer between 2005 and 2008. BCS=breast conserving surgery
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